🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to health experts.

An International Health Concern

Cases of gonorrhoea are on the rise around the world, with figures suggesting more than 82 million infections per year. Particularly high rates are reported in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely advancement in the face of rising global incidence, escalating drug resistance and the highly restricted therapeutic options at this time.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Authorization

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to major issues, including infertility. Experts hope that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This medication, which is employed against urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This approval marks a huge turning point in the management of superbug gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Results and Worldwide Availability

According to data published in a prominent scientific publication, the new drug cured over nine in ten of uncomplicated infections. This places it at an comparable level with the typical regimen, which involves a dual-drug approach. The study involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to register and commercialise the drug in a wide range of developing nations.

Medical professionals directly involved have expressed optimism. Access to a single-dose, oral treatment like this is hailed as a "game-changer" for public health efforts. This is considered essential to lessen the impact of the infection for people and to halt the transmission of extremely resistant gonorrhoea around the world.